Tenax Therapeutics, Inc. · NASDAQ:TENX
Tenax Therapeutics — Oxygen Biotherapeutics — FY2011 Earnings Presentation
12 slides from Tenax Therapeutics's earnings presentation, Jul 15, 2011
Slide 1: OXBT FY2011 Year End Financial Results Conference Call
OXBT FY2011 Year End Financial Results Conference Call July 15, 2011
Slide 2: Forward-looking statements
This discussion may contain forward-looking statements. These statements are subject to factors which may cause our plans to change or actual results to differ materially from those described in this presentation. Additional information regarding these factors is discussed in our Annual Report on ou
Slide 3: Topical Update, Cosmetic, Neurological, Financial, Milestones
Topical Update Cosmetic/DERMACTYE Update Neurological Update Financial Update Targeted Milestones 3
Slide 4: PFC creams for wounds, burns, itching, acne and dermatitis
Anecdotal data suggests potential to use our PFC creams for wounds, burns, itching, acne and dermatitis Currently finalizing details with CRO in India to conduct studies focused on 3 indications Capital raised will support these trials 4
Slide 5: Hackensack wound healing research contract
Research contract with Hackensack University Medical Center to study wound healing properties of full-thickness excisional wounds and partial thickness burns underway 2-year program funded by DoD 5
Slide 6: DERMACYTE sales update
Over $300,000 in sales for FY’11 Domestic sales by sales reps are growing with Florida taking the lead Reorder rates of approximately 30% Agreement with DERMACYTE Switzerland to purchase product and sell in EU, Switzerland and Russia Mexican distributor placed first order just after the qu
Slide 7: Preclinical work under $2M US Army grant
Initiating preclinical work associated with $2m grant from the US Army Preclinical trials will support our traumatic brain injury program Examine effects of Oxycyte on immune system, platelet function & distribution, safety and efficacy of platelet transfusion Evaluate the pharmacokinetics o
Slide 8: Clinical sites in India and cGMP scale-up
Recently approved to open clinical sites in India Purpose of expansion is to lower costs and boost enrollment Started the scale-up process for cGMP manufacture of Oxycyte 8
Slide 9: US Navy studies
Conducted by US Navy Two dose range studies completed – await results Two studies underway to evaluate effect of hyperbaric oxygen therapy after treatment with Oxycyte 9
Slide 10: Year ended April 30 financial results
Year Ended April 30, 2011 2010 Net revenue 103,167 8,353 Total Op. Exp. 10,665,844 10,209,849 Net Loss 10,448,296 10,507,376 Net loss per share (0.45) (0.54) TSO 23,346,496 19,485,065 10
Slide 11: Targeted milestones
Begin dermatology studies in India Finalize new cosmetic formulations and expand the product line by year-end Secure our financial base 11
Slide 12: Thank you!
Thank you! www.dermacyteUS.com www.oxybiomed.com
Oxygen Biotherapeutics — FY2011 Earnings Presentation on 6ix